Optimal dose-finding designs with correlated continuous and discrete responses

被引:30
|
作者
Fedorov, Valerii [2 ]
Wu, Yuehui [2 ]
Zhang, Rongmei [1 ]
机构
[1] Univ Penn, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA
[2] GlaxoSmithKline, Biomed Data Sci, Res Stat Unit, Collegeville, PA 19426 USA
关键词
multiple endpoints; bivariate probit models; optimal experimental design; model-based dose-finding approaches; utility functions; penalty functions; BAYESIAN DECISION PROCEDURES; LATENT VARIABLE MODELS; ADAPTIVE DESIGNS; CLINICAL-TRIALS; MIXED DISCRETE; BINARY; REGRESSION; EFFICACY; OUTCOMES; ESCALATION;
D O I
10.1002/sim.4388
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
In dose-finding clinical studies, it is common that multiple endpoints are of interest. For instance, in phase I/II studies, efficacy and toxicity are often the primary endpoints, which are observed simultaneously and which need to be evaluated together. Motivated by this, we confine ourselves to bivariate responses and focus on the most analytically difficult case: a mixture of continuous and categorical responses. We adopt the bivariate probit doseresponse model and quantify our goal by a utility function. We study locally optimal designs, two-stage optimal designs, and fully adaptive designs under different ethical and cost constraints in the experiments. We assess the performance of two-stage designs and fully adaptive designs via simulations. Our simulations suggest that the two-stage designs are as efficient as and may be more efficient than the fully adaptive designs if there is a moderate sample size in the initial stage. In addition, two-stage designs are easier to construct and implement and thus can be a useful approach in practice. Copyright (C) 2011 John Wiley & Sons, Ltd.
引用
收藏
页码:217 / 234
页数:18
相关论文
共 50 条
  • [21] Implementation of maximin efficient designs in dose-finding studies
    Fackle-Fornius, Ellinor
    Miller, Frank
    Nyquist, Hans
    PHARMACEUTICAL STATISTICS, 2015, 14 (01) : 63 - 73
  • [22] A Likelihood Perspective on Dose-Finding Study Designs in Oncology
    Zhang, Zhiwei
    PHARMACEUTICAL STATISTICS, 2025, 24 (02)
  • [23] Compound designs for dose-finding in the presence of nondesignable covariates
    Biswas, Atanu
    Lopez-Fidalgo, Jesus
    PHARMACEUTICAL STATISTICS, 2013, 12 (02) : 92 - 101
  • [24] Continual reassessment and related designs in dose-finding studies
    Iasonos, Alexia
    O'Quigley, John
    STATISTICS IN MEDICINE, 2011, 30 (17) : 2057 - 2061
  • [25] Adaptive designs for Phase I dose-finding studies
    Zhou, Yinghui
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2010, 24 (02) : 129 - 138
  • [26] Optimal Stopping of Adaptive Dose-Finding Trials
    Nasrollahzadeh, Amir Ali
    Khademi, Amin
    SERVICE SCIENCE, 2020, 12 (2-3) : 80 - 99
  • [27] Dose-finding designs for trials of molecularly targeted agents and immunotherapies
    Chiuzan, Cody
    Shtaynberger, Jonathan
    Manji, Gulam A.
    Duong, Jimmy K.
    Schwartz, Gary K.
    Ivanova, Anastasia
    Lee, Shing M.
    JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2017, 27 (03) : 477 - 494
  • [28] Dose-finding designs for cumulative toxicities using multiple constraints
    Lee, Shing M.
    Ursino, Moreno
    Cheung, Ying Kuen
    Zohar, Sarah
    BIOSTATISTICS, 2019, 20 (01) : 17 - 29
  • [29] Escalation, group and A+B designs for dose-finding trials
    Ivanova, Anastasia
    STATISTICS IN MEDICINE, 2006, 25 (21) : 3668 - 3678
  • [30] Embracing model-based designs for dose-finding trials
    Sharon B Love
    Sarah Brown
    Christopher J Weir
    Chris Harbron
    Christina Yap
    Birgit Gaschler-Markefski
    James Matcham
    Louise Caffrey
    Christopher McKevitt
    Sally Clive
    Charlie Craddock
    James Spicer
    Victoria Cornelius
    British Journal of Cancer, 2017, 117 : 332 - 339